(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 15.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.94%.
Halozyme Therapeutics's revenue in 2024 is $829,253,000.On average, 5 Wall Street analysts forecast HALO's revenue for 2024 to be $121,035,501,530, with the lowest HALO revenue forecast at $120,295,859,296, and the highest HALO revenue forecast at $122,583,778,688. On average, 6 Wall Street analysts forecast HALO's revenue for 2025 to be $140,358,654,882, with the lowest HALO revenue forecast at $136,378,512,184, and the highest HALO revenue forecast at $152,757,935,104.
In 2026, HALO is forecast to generate $165,193,740,868 in revenue, with the lowest revenue forecast at $164,113,827,696 and the highest revenue forecast at $166,656,664,936.